[Combined hepatic artery chemoembolization and portal vein chemotherapy after radical resection of hepatocellular carcinoma to prevent recurrence].
OBJECTIVE
To study the value of combined hepatic artery chemoembolization (HACE) and portal vein chemotherapy (PVC) after radical resection of hepatocellular carcinoma (HCC) to prevent recurrence.


METHODS
From August 1991 to July 1995, 81 HCC patients were undergone radical tumor resection. After operation, combined treatment with HACE and PVC was given in group I (28 cases), HACE alone in group II (30 cases), nothing in group III (28 cases). All patients were followed up over 3 years.


RESULTS
Recurrence rate at one year after surgery was significantly lower in group I and II than in group III; at two years, it was lower in group I than in group II and III. Survival rate at one year was notably higher in group I and II than in group III; at 2 years, it was higher in group I than in group II and III. Recurrence rate and survival rate were similar in group I and group II at 3 and 5 years after surgery. Tumor larger than 5 cm, no capsule, multiple foci, AFP > 400 micrograms/L were high risk factors of postoperative recurrence.


CONCLUSIONS
After radical resection of HCC, combined use of HACE and PVC is superior to HACE alone to reduce recurrence rate and to increase survival rate within 2 years after operation. Such remarkable difference no more exists at 3 and 5 years following operation.
Li
H
H
Department of Surgery, Memorial Hospital, Sun Yat-sen University of Medical Sciences, Guangzhou 510120, China.
Ou
Q
Q
Chen
J
J
D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D003131:Combined Modality Therapy; D004333:Drug Administration Routes; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011169:Portal Vein; D012189:Retrospective Studies; D055502:Secondary Prevention; D015996:Survival Rate; D016896:Treatment Outcome